A method of measuring APP669-711, including involving immobilizing, to a support, a first antibody capable of immunospecifically binding to an N terminus of APP669-711; blocking the support to which the first antibody is immobilized, with a blocking agent; bringing APP669-711 in the sample into contact with the first antibody thus immobilized, and thereby allowing APP669-711 to bind to the first antibody; removing the sample that is not bound; bringing a second antibody capable of immunospecifically binding to a C terminus of APP669-711, into contact with APP669-711 bound to the first antibody thus immobilized, and thereby allowing the second antibody to bind to APP669-711; removing the second antibody that is not bound; and detecting the presence of the second antibody bound to APP669-711.

Systems are described, based on a primary binding compound and a secondary binding compound used in combination with a support to detect a target in a sample. The systems includes at least one support structure, at least one small primary support portion containing at least one molecule covalently bound to a visual colloidal marker, a plurality of secondary support portions comprising secondary binding compounds that are covalently bound to the support portions and chemically active, at least one pH litmus indicator, at least one pH strip, a buffer for lateral flow on the porous membrane support that allows preservation and activity of binding compounds.

The present invention provides methods, devices, and compositions to rapidly detect analytes, including small analytes, using a lateral flow device. Described herein is such a lateral flow device that can detect and quantify vitamin D in a whole blood, serum, or plasma sample by employing a sandwich-based immunoassay.

Antibodies against a virus can be detected in a sample using at least one reagent comprising at least one capture molecule immobilized to a particle, which reagent in the presence of such antibodies forms an anti-virus antibody-capture molecule complex, wherein the presence of said complex is qualitatively, quantitatively or semi-quantitatively determined by measuring a signal generated by said complex, said particle is a nanoparticle and said capture molecule is immobilized to said nanoparticle simultaneously with a co-molecule which is smaller than said capture molecule. When the capture molecule is a virus epitope, the co-molecule preferably has a molecular weight in the range of 50-1500 Da, wherein said co-molecules when immobilized on said nanoparticle separate the capture molecules so that an average distance between two adjacent capture molecules is greater than a distance between the antigen binding sites of the anti-virus antibody to be detected.

The present invention provides a non-invasive method of diagnosing colorectal cancer in a subject. The method comprises determining the blood concentrations of the proteins TRIM28, PLOD1 and CEACAM5 (and optionally P4HA1) in a subject. An analysis of the concentrations is performed to determine whether the subject has colorectal cancer.

Point-of-care assays for quantitatively measuring the amount of small analytes, such as opioids, tetrahydrocannabinol (“THC”), or hormones, in a biological sample are disclosed. The assays are capable of non-competitive detection of a small analyte using binding agents that selectively bind the analyte and capture agents that selectively bind a complex of the binding agent and analyte but do not bind either free binding agent or free analyte. The assay is capable of simultaneous diction of multiple analytes for multiplex analysis and quantitative control. Quantitative measurements are obtained by plotting results against a response surface calculated from a plurality of analyte standards and adjusted using internal controls.

Disclosed herein are methods and compositions for prognosing or diagnosing an obstructive renal dysfunction or ureteropelvic junction obstruction (UPJO) in a subject, involving detecting in a urine sample from a subject one or more proteins selected from the group consisting of Immunoglobulin superfamily containing leucine-rich repeat protein (ISLR);

Nicotinate-nucleotide pyrophosphorylase [carboxylating] (QPRT); Prostaglandin reductase 1 (PTGR1); Vascular cell adhesion protein 1 (VCAM1); and Ficolin-2 (FCN2), or detectable portions thereof to identify the subject as at risk of or having an obstructive renal dysfunction or UPJO.

The present invention relates to methods for detecting the presence or absence of a gynaecological cancer in a subject, the method (a) comprising obtaining a non-invasive sample isolated from the subject; and (b) treating the non-invasive sample to release at least one biomarker from cells in the non-invasive sample. The present invention also relates to lysis buffers, monoclonal antibodies, and kits that can be used in such methods. The present invention also relates to a method for diagnosing a subject as having a gynaecological cancer or a benign gynaecological condition. The present invention also relates to a method for distinguishing between a non-invasive sample associated with a gynaecological cancer and a non-invasive sample associated with a benign gynaecological cancer. The present invention further relates to a method for stratifying a subject into one of two treatment groups.

The present invention provides methods, devices, and compositions to rapidly detect analytes, including small analytes, using a lateral flow device. Described herein is such a lateral flow device that can detect and quantify vitamin D in a whole blood, serum, or plasma sample by employing a sandwich-based immunoassay.

Disclosed herein systems, apparatuses and methods for the collection and testing of biological samples, and more specifically to rapid and simple methods for diagnosis of various diseases, conditions, or symptoms via the testing of collected biological samples on paper devices.